Page 46 - memoria2020online
P. 46
Memoria de actividades
2020
6
Comunicaciones a Congresos en los
que ha participado GEICAM en 2020
INVESTIGACIÓN Y PUBLICACIONES - Comunicaciones a Congresos AACR Virtual annual Woodward N, Goodwin A, (gLOH) on efficacy in Phase 3
Meeting. Yerushalmi R, Roché H,
Im Y, Eiermann W, Quek EMBRACA study of talazoparib
Oral R.G, Usari T, Lanzalone S,
Czibere A, Blum J.L, Martin in patients (pts) with HER2-
Crown J, Jacot W, Collins M, Ettl J.
D.M, Coate L, Saetersdal A, negative (HER2−) advanced
Kennedy J, Kelly C, Cantos Talazoparib (TALA) in germline
Sanchez De Ibarguen B, breast cancer (ABC) and a
Andrés Conejero R, Costa BRCA1/2 (gBRCA1/2)-mutated
L, Brito M, Keane M, germline BRCA1/2 (gBRCA1/2)
Sanchez Rovira P, Martin human epidermal growth factor
M, O’Connor M, Moulton B, mutation
O’Donovan N, Hernando A, receptor 2 negative (HER2-)
Nolan M, Parker I, Gullo G, AACR Virtual annual Meeting. April
Hennessy B. advanced breast cancer (ABC): 27-28, 2020. Session VCTPL07 -
Breast Cancer Therapy. Abstract
A Phase III Randomized Final overall survival (OS) CT072.
Study of Paclitaxel (T) and Proceedings of the Annual Meeting
Trastuzumab (H) Versus T, H results from randomized Phase of the American Association for
and Lapatinib (L) in First Line Cancer Research 2020; 2020 Apr
Treatment of HER2+ Metastatic 3 EMBRACA trial 27-28 and Jun 22-24. Philadelphia
Breast Cancer (MBC). (PA): AACR; Cancer Res 2020;80(16
AACR Virtual annual Meeting. Suppl):Abstract nr CT072.
AACR Virtual annual Meeting. April April 27-28, 2020. Session
27-28, 2020. Session VPO. CT03 - VCTPL07 - Breast Cancer https://cancerres.aacrjournals.org/
Phase III Clinical Trials. Abstract Therapy. Abstract CT071.
CT212. Proceedings of the Annual Meeting content/80/16_Supplement/CT072
Proceedings of the Annual Meeting of the American Association for
of the American Association for Cancer Research 2020; 2020 Apr ESMO BC
Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia Virtual Meeting
27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16
(PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT071. Poster
Suppl):Abstract nr CT212.
https://cancerres.aacrjournals.org/ https://cancerres.aacrjournals.org/ Kahan Z, Gil-Gil M, Ruíz-
content/80/16_Supplement/CT212 Borrego M, Carrasco E,
content/80/16_Supplement/CT071 Ciruelos E, Muñoz M,
Oral Bermejo B, Margeli M,
Oral Antón A, Casas M, Calvo
Litton J.K, Hurvitz S.A, L, de la Haba J, Ramos M,
Mina L.A, Rugo H.S, Lee K, Litton J.K, Laird A.D, Álvarez López I, Gal-Yam
Gonçalves A, Diab S, Rugo H.S, Ettl J, Hurvitz E, Gauthier E, Corsaro M,
S.A, Martin M, Roché H, Rodrigálvarez G, Zielinski C,
46 Im Y, Goodwin A, Blum Martín M.
J.L, Eiermann W, Chen Y,
Lanzalone S, Chelliserry Quality of life (QoL) with
J, Czibere A, Albacker L.A,
Frampton G.M, Mina L.A. Palbociclib (PAL) plus
Exploration of impact of tumor endocrine therapy (ET) versus
BRCA zygosity and genomic (vs) Capecitabine (CAP) in
loss-of-heterozygosity
